The Role of Dexmedetomidine for the Prevention of Acute Kidney Injury in Critical Care-Reference-Cited by-同舟云学术

The Role of Dexmedetomidine for the Prevention of Acute Kidney Injury in Critical Care

Published:2021-07-20 Issue: Volume: Page:97-106
ISSN:2053-4248
Container-title:EMJ Nephrology
language:
Short-container-title:EMJ Nephrol

Author:

Ruegg Gion¹,Luethi Nora²,Cioccari Luca³

Affiliation:

1. Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

2. Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Prahran, Australia

3. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Prahran, Australia

Abstract

Acute kidney injury (AKI) occurs in up to 50% of patients admitted to the intensive care unit and is associated with increased mortality. Currently, there is no effective pharmacotherapy for prevention or treatment of AKI. In animal models of sepsis and ischaemia-reperfusion, α2-agonists like dexmedetomidine (DEX) exhibit anti-inflammatory properties and experimental data indicate a potential protective effect of DEX on renal function. However, clinical trials have yielded inconsistent results in critically ill patients. This review discusses the pathophysiological mechanisms involved in AKI, the renal effects of DEX in various intensive care unit-related conditions, and summarises the available literature addressing the use of DEX for the prevention of AKI.

Publisher

European Medical Group

Reference86 articles.

1. Ronco C et al. Acute kidney injury. Lancet 2019;394(10212):1949-64.

2. Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical Phenotypes. Clin Biochem Rev. 2016;37(2):85-98.

3. Kellum JA et al. Recovery after acute kidney injury. Am J Respir Crit Care Med. 2017;195(6):784-91.

4. Meersch M et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551-61.

5. Weerink MAS et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893-913.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of dexmedetomidine on mortality in critically ill patients with acute kidney injury: a retrospective propensity score matching analysis;BMJ Open;2023-11

2. Early recognition and prevention of acute kidney injury in hospitalised children;The Lancet Child & Adolescent Health;2023-09